Treatment With Cannabis Oil Containing CBD Only or 20:1 CBD:THC vs. Placebo of Persons With ADHD
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
ADHD is the most frequent neuro-developmental disorder in childhood and often continues into
adolescence and adulthood.
Indicated drug treatments for ADHD fall into 2 categories: stimulants (such as
methylphenidate and amphetamines) and non-stimulants (such as atomoxetine, guanfacine and
clonidine) but some persons cannot tolerate their secondary effects or find them
non-effective.
In the last decade, medical cannabis products have been researched as possible treatment for
neurological and mental diseases such as: Post trauma disorder (PTD), autism (ASD), epilepsy,
fibromyalgia (FM) and more.
Data on the effects of cannabidiol rich cannabis extract use for ADHD seems promising but is
still limited. The aim of this study is to investigate if oral cannabinoids given to adults
with ADHD affect the symptoms of the disorder.
The main objectives of the study are: 1) to characterize the effects of treatment with
cannabis oil on symptoms of ADHD; 2) to compare safety and efficacy of cannabis oil products
with different CBD,Cannabidivarin (CBDV), cannabigerol (CBG) and THC ratio; 3) and to measure
endocannabinoids, THC and CBD and metabolites levels in the blood of the participants.
In this study, participants diagnosed with ADHD will be treated with canabidiol-rich cannabis
oil and will follow up weekly during approx.1 month (the study period). Blood tests will be
performed before and after treatment. Blood tests include blood count, blood chemistry,
hormones profile, phyto- and endo- cannabinoids and their metabolites. Test of Variables of
Attention test (TOVA) will be administrated before and after treatment